Pharmaceutical intelligence for consultancies

Focus on your clients and expand your business opportunities. We’ll help you build a complete picture of the rapidly changing pharmaceutical market with our insight and expertise.

With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. Pharma Intelligence will help you make smart decisions and stay ahead of a fast changing market.

What we offer

As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our wide range of solutions cover early phase, clinical R&D, portfolio and strategy, regulatory and commercial planning and analysis.

We cover the life sciences business from drug and device discovery and development to regulatory approval, and drug reimbursement to lifecycle management. And we give you access to past, current and future trends and analysis.

How it helps

Whether you’re working on your next business pitch, engaging on a project for an existing client or working on due diligence for a proposed merger or acquisition; our pharmaceutical intelligence helps you meet the demands of dynamic markets and changing customer needs, with:

Expert analysis of key pharma sectors
In-depth knowledge from drug discovery to market access
Global coverage including digital health, R&D, and emerging markets
Precise analysis and data
Customized reports

Scrip

Opdivos EU Colorectal Cancer is a Setback but More Than Offset By Potential Gains

By Ian Schofield 29 Nov 2022

Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.

Scrip

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

By Jessica Merrill 14 Nov 2022

The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.

Datamonitor Healthcare

Multiple Myeloma Pricing, Reimbursement, and Access

14 Nov 2022

Disease management and treatment programmes change, as research evolves and new discoveries are made. Your market access strategies must evolve too.

Scrip

Sanofi's €10bn Dupixent Plan: 'We're Going To Put The JAKs Properly In Their Place'

By Jessica Merrill 14 Nov 2022

Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.

Scrip

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

By Mandy Jackson 14 Nov 2022

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Datamonitor Healthcare

Acute Myeloid Leukemia Market Outlook Seminar

By Dominique Fontanilla 14 Nov 2022

There has been little change to standard treatment for AML in recent years; however, 2017 saw a flurry of new targeted drug approvals, sparking significant market growth. Patient age remains the biggest factor in driving treatment decisions for AML. Cases of AML are expected to increase, and prognosis remains poor – especially among older adults. Drug developers are targeting patient segments with high unmet clinical need to gain access to the AML market and the budget impact of AML is expected to grow considerably.

Datamonitor Healthcare

Understand Market Access Trends in the US, Europe and Emerging Markets

14 Nov 2022

This essential whitepaper looks at how increased drug spending and a rising desire for expenditure controls are influencing access dynamics across key markets. It is available to you now, for free.

Generics Bulletin

Chirag Patel And Chintu Patel Return As Co-CEOs Of Amneal

By David Wallace 25 Oct 2022

Chirag Patel and Chintu Patel have returned to being co-CEOs of Amneal, just over a year after the firm completed its merger with Impax. Rob Stewart – who was president and CEO of Amneal – and executive chairman Paul Bisaro have resigned from the roles.

Scrip

AstraZeneca Plans $630m Korea Investment Amid Favorable Policies

By Jung Won Shin 25 Oct 2022

AstraZeneca plans hefty investment in South Korea’s biomedical sector over next few years, in a signal of multinationals' improved sentiment over the government’s recently announced plans to nurture the bio-health industry as a major growth engine.

Pink Sheet

What Breast Cancer Drug Developers Need to Know Now About Regulatory Policies

21 Oct 2022

As biopharma continues to make progress developing novel and more targeted cancer therapies, regulators are responding with innovative and collaborative approaches to reviewing cancer products, aiming to resolve questions earlier and review products more quickly. Pink Sheet closely covers these programs, helping readers understand the expectations, challenges and opportunities, as well as lessons from companies putting policy into practice. This ebook takes some of our recent articles on special review mechanisms and regulators’ data expectations.

Scrip

Scrip Asks...What Does 2020 Hold For Biopharma? Part 1: Therapeutic Advances

By Eleanor Malone 20 Oct 2022

Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.

Biomedtracker, Datamonitor Healthcare

COVID-19 24 hour webinar recordings

31 Aug 2022

Catch up on any missed COVID-19 24 hour webinar sessions

Datamonitor Healthcare

Profitability Assessment of Branded Generic Inhalers

By Ljlal Syed, Mark Lansdell and David Abramson 28 Jul 2022

This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic

Datamonitor Healthcare

Immuno-Oncology Overview

By Colin White, Robert Jeng & Jolene Lau 28 Jul 2022

This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well

Datamonitor Healthcare

Webinar: Manufacturing Challenges Facing Cell and Gene Therapy

By Amanda Micklus 20 Jun 2022

As more regenerative medicine products approach clinical testing and commercialization, seize this opportunity to hear detailed insights and industry best practices from preeminent sector experts. You’ll gain a deep understanding of numerous nurdles unique to bringing durable, curative therapies to patients in need.

Pharmaceutical intelligence for consultancies

Your trusted pharma partner

Our unique strengths

Understand your clients’ world

Stay on top of the details

Think ahead

Deliver tailored solutions

Benefit from a dedicated service

Relevant products

Below are the Product Brand List

HBW Insight: Health, Beauty and Wellness

Generics Bulletin

Pharma Intelligence latest insights

Opdivos EU Colorectal Cancer is a Setback but More Than Offset By Potential Gains

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

Multiple Myeloma Pricing, Reimbursement, and Access

Sanofi's €10bn Dupixent Plan: 'We're Going To Put The JAKs Properly In Their Place'

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

Acute Myeloid Leukemia Market Outlook Seminar

Understand Market Access Trends in the US, Europe and Emerging Markets

Chirag Patel And Chintu Patel Return As Co-CEOs Of Amneal

AstraZeneca Plans $630m Korea Investment Amid Favorable Policies

What Breast Cancer Drug Developers Need to Know Now About Regulatory Policies

Scrip Asks...What Does 2020 Hold For Biopharma? Part 1: Therapeutic Advances

COVID-19 24 hour webinar recordings

Profitability Assessment of Branded Generic Inhalers

Immuno-Oncology Overview

Webinar: Manufacturing Challenges Facing Cell and Gene Therapy

Next steps

This is Contactus Section

Request a live demo

Speak to Sales

Client Services

Pharma Report Store